DGAP-News

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share

DGAP-News: Dermapharm Holding SE / Key word(s): AGM/EGM Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share 01.06.2022 / 16:26 The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 2.17 per share

           - Board of Management and Supervisory Board actions ratified with large majority

- Shareholders resolve dividend payment of EUR 2.17 per share

- Distribution ratio: approximately 55% of consolidated net profit

- Previous Supervisory Board members reappointed

- 2022 outlook confirmed

Grünwald, 1 June 2022 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2022 Annual General Meeting. 80.43% of the share capital was in attendance at the virtual Annual General Meeting. The majority of shareholders approved the management's proposals under every agenda item.

The Annual General Meeting ratified the actions of the Board of Management and of the Supervisory Board for financial year 2021 with a 98.54% and 92.26% majority of votes cast, respectively. At the recommendation of the Board of Management, the Annual General Meeting resolved to distribute a dividend of EUR 2.17 per share. The total distribution amounts to EUR 116.8 million, representing a distribution ratio of approximately 55%.

The election of the Supervisory Board was also held at Annual General Meeting, and the three present members, Mr Wilhelm Beier, Dr Erwin Kern and Mr Lothar Lanz, were reappointed. The term of office of all Supervisory Board members expires at the end of the 2026 Annual General Meeting.

Grant Thornton AG Wirtschaftsprüfungsgesellschaft was once again elected to serve as auditors. The detailed results of the voting for each agenda item are available in the Annual General Meeting section of the Company website https://ir.dermapharm.de.

In their retrospective on financial year 2021, the Board of Management and the Supervisory Board highlighted the Company's extraordinary performance, which had proved a highly challenging feat to achieve, particularly in the second half of the year, in light of supply bottlenecks and price increases. With this in mind, they expressed their gratitude to all employees for their tireless efforts in 2021. The Board of Management concluded by providing an outlook for the remainder of 2022.